市場調査レポート

商品コード

肺がん治療の世界市場：市場規模・予測、世界・地域別シェア、動向、成長機会、分析範囲：治療の種類別・適応症別・エンドユーザー別・地域別

Lung Cancer Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, Indication, End User, and Geography

出版日: 2023年10月30日 | 発行: The Insight Partners

| ページ情報: 英文 206 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 4,550 712,439円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 6,550 1,025,599円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 8,550 1,338,759円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.58円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の肺がん治療市場は、2022年の310億1,800万米ドルから2030年には804億9,300万米ドルに成長すると予想されており、2022年から2030年までのCAGRは12.7%を記録すると予測されています。

個別化医療の一種である標的療法は、がん細胞を直接標的とするように設計された2種類以上の薬剤の組み合わせです。切除療法や化学療法などの治療法は、感染細胞とともに健康な細胞も破壊するため、患者全体の状態に影響を及ぼす可能性があります。標的療法は、がん細胞を選択的に死滅させ、健康な細胞の機能は妨げないように設計されています。最近の医療技術の発達に伴い、肺がんの治療に標的療法を用いることへの注目は著しく高まっています。科学者たちは、がん細胞の制御不能な増殖の原因となる肺がん細胞の突然変異の研究に注力しています。2021年5月、米国食品医薬品局は成人非小細胞肺がん患者に対する初の治療薬であるルマクラス (ソトラシブ) を承認しました。この治療法は、KRAS G12C変異を有し、少なくとも1回の前治療として全身療法を受けている患者に投与されます。各社はEGFR、ALK、ROS1、KRASなどのバイオマーカーを利用して標的治療薬を開発しており、がん細胞内の変異の種類を検出するのに役立っています。このように、企業が標的療法の開発に注力するようになっていることと、肺がん患者に対するその利点についての認識が高まっていることが相まって、今後数年間、肺がん治療市場に新たな動向をもたらすと予想されます。

肺がん検診・治療に対する政府の取り組みが肺がん治療市場の成長を牽引

ジョンソン・エンド・ジョンソンが発表した記事によると、肺がんは世界におけるがん死亡の主な原因であり、一般的に後期に発見されます。初期段階では、肺がん患者は目立った症状を示さないため、発見されたケースのほぼ50%において、がんはすでに転移段階に達しています。この肺がんの深刻さを受けて、各国政府は早期発見と検診を奨励し、肺がんの早期治療を行うためのイニシアチブの導入に力を入れています。

米国予防サービス専門委員会 (USPSTF) によると、米国では、50～80歳の喫煙歴が年間20箱あり、現在喫煙しているか、過去15年以内に禁煙している人が肺がんを発症しやすいです。したがって、米国予防サービス専門委員会 (USPSTF) は、肺がんの早期発見を確実にするため、これらの人々に毎年低線量コンピュータ断層撮影法 (LDCT) による肺がん検診を受けることを推奨しています。さらに、2022年7月、米国のバイデン政権は、メディケアサービスが適用される患者のがん治療を改善し、治療費を下げることを目的とした新しいモデルを導入しました。

2021年7月、キャンサー・オーストラリアは保健高齢者医療省と提携し、オーストラリアにおける肺がん検診プログラムの実現可能性を評価しました。実現可能性評価の結果が良好であったため、2023年5月、オーストラリア政府保健・高齢者医療省は、全国肺がん検診プログラムの実施のため、2023年から2024年にかけて2億6,380万米ドルを投資することを宣言しました。このプログラムを通じて、保健・高齢者医療省は肺がんの予防と早期発見に重点を置いています。さらに、欧州保健連合 (EU) が導入したBeating Cancer Planは、肺がん患者の予防、治療、ケアに焦点を当てることで、疾患経路全体に取り組むことを目的としています。

このように、肺がん患者の早期発見と適切な治療を目的とした各国政府による取り組みが急増していることが、肺がん治療市場の成長を後押ししています。

肺がん治療市場は、治療の種類別、適応症別、エンドユーザー別、地域別によって区分されます。肺がん治療市場は、ワクチンの種類別に非侵襲性と低侵襲性に二分されます。低侵襲性セグメントはさらに、高周波アブレーション、マイクロ波アブレーション、熱アブレーション、冷凍アブレーション、化学アブレーション、光線力学的アブレーション、その他に分類されます。肺がん治療市場は、適応症別に非小細胞肺がんと小細胞肺がんに区分されます。エンドユーザー別では、病院、腫瘍クリニック、研究センター、その他に区分されます。

地域別に見ると、市場は北米、欧州、アジア太平洋、中東・アフリカ、中南米に区分されます。北米は肺がん治療市場で最大の市場シェアを占めています。北米は、喫煙の増加、タバコの消費、工業化による大気汚染の増加に起因する肺がん患者の増加により、大きな市場シェアを占めています。米国における肺がん治療市場の成長は、主に肺がん罹患率の増加、製品の上市、政府の取り組みによってもたらされます。肺がんは米国で2番目に多いがんです。米国がん協会 (American Cancer Society, Inc.) によると、2023年現在、米国の成人～238,340人 (男性117,550人、女性120,790人) が肺がんと診断され、また～127,070人 (男性67,160人、女性59,910人) が肺がんが原因で死亡しています。肺がんはがんによる死亡の5人に1人を占め、米国におけるがんによる死亡の主な原因となっています。同じ情報源によると、肺がんの診断の81%はNSCLCです。このように、米国における肺がん罹患率の増加は、米国の肺がん治療市場の成長を後押ししています。

企業による肺がん治療のためのさまざまな製品の発売も、市場の成長を後押ししています。例えば、2021年5月、米国FDAはルマクラス (ソトラシブ) を成人非小細胞肺がん患者に対する初の標的治療薬として承認しました。これは、非小細胞肺がん (NSCLC) における変異の～25%を報告するKRAS変異を有する腫瘍に対して承認された最初の標的療法です。さらに、2021年5月、米国FDAは、EGFRエクソン20挿入変異を有する局所進行性または転移性NSCLCの成人患者を対象に、上皮成長因子 (EGF) およびMET受容体に対する二重特異性抗体であるamivantamab-vmjw (Rybrevant) を早期承認しました。

2023年5月、デジタル戦略室が管理するホワイトハウスの公式ウェブサイトwhitehouse.govに掲載された報告書によると、地域がんセンター協会 (ACCC) とアストラゼネカは、"アパラチア地方肺がん検診イニシアチブ"を通じて、アメリカの地方における肺がん検診を推進するために、個人を中心とした持続可能なアプローチを開発・実施するためのパートナーシップを締結しました。アパラチア地域 (ウェストバージニア州全域と他の12州の一部を含む) のがん死亡率は、米国の他の地域よりも10%高いです。このイニシアチブは、肺がんの5年生存率を2倍にすることを目的としています。このような取り組みが米国の肺がん治療市場の成長に寄与しています。

ClinicalTrails.com、米国疾病予防管理センター (CDC)、米国食品医薬品局 (FDA)、米国予防サービス作業部会 (USPSTF) などは、肺がん治療市場に関するレポート作成時に参照した主要な一次情報源および二次情報源です。

北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- ロシア
- その他欧州
アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- 東南アジア
  - シンガポール
  - マレーシア
  - インドネシア
  - ベトナム
  - カンボジア
  - フィリピン
  - 他の東南アジア諸国
- その他アジア太平洋
中東・アフリカ
- サウジアラビア
- 南アフリカ
- アラブ首長国連邦 (UAE)
- その他中東・アフリカ
中南米
- ブラジル
- アルゼンチン
- その他中南米

第11章肺がん治療市場：業界情勢

肺がん治療市場の成長戦略
無機的成長戦略
有機的成長戦略

第12章企業プロファイル

Medtronic Plc
RF Medical Co Ltd
Johnson & Johnson
Merck KGaA
Sun Pharmaceutical Industries Ltd
Bioventus Inc
Olympus Corp
Meiji Seika Pharma Co Ltd
Advanz Pharma Corp

第13章付録

図表

List Of Tables

Table 1. Lung Cancer Therapy Market Segmentation
Table 2. Global Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Lung Cancer Therapy Market, by Therapy Type- Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 6. North America Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 7. US Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. US Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 9. US Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 10. US Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 19. Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 20. Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 21. Europe Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 22. Europe Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 23. UK Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 24. UK Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 25. UK Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 26. UK Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 31. France Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 32. France Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 33. France Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 34. France Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 37. Italy Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 38. Italy Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 43. Russia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 44. Russia Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 45. Russia Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 46. Russia Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Europe Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 49. Rest of Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 50. Rest of Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 51. Asia Pacific Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 52. Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 53. Asia Pacific Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 54. Asia Pacific Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 55. China Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 56. China Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 57. China Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 58. China Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 59. Japan Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 60. Japan Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 61. Japan Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 62. Japan Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 63. India Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 64. India Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 65. India Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 66. India Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 67. Australia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 68. Australia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 69. Australia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 70. Australia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 71. South Korea Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 72. South Korea Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 73. South Korea Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 74. South Korea Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 75. Southeast Asia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 76. Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 77. Southeast Asia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 78. Southeast Asia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 79. Singapore Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 80. Singapore Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 81. Singapore Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 82. Singapore Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 83. Malaysia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 84. Malaysia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 85. Malaysia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 86. Malaysia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 87. Indonesia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 88. Indonesia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 89. Indonesia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 90. Indonesia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 91. Vietnam Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 92. Vietnam Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 93. Vietnam Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 94. Vietnam Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 95. Cambodia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 96. Cambodia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 97. Cambodia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 98. Cambodia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 99. Philippines Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 100. Philippines Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 101. Philippines Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 102. Philippines Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 103. Rest of Southeast Asia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 104. Rest of Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 105. Rest of Southeast Asia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 106. Rest of Southeast Asia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 107. Rest of Asia Pacific Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 108. Rest of Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 109. Rest of Asia Pacific Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 110. Rest of Asia Pacific Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 111. Middle East & Africa Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 112. Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 113. Middle East & Africa Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 114. Middle East & Africa Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 115. Saudi Arabia Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 116. Saudi Arabia Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 117. Saudi Arabia Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 118. Saudi Arabia Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 119. South Africa Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 120. South Africa Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 121. South Africa Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 122. South Africa Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 123. UAE Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 124. UAE Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 125. UAE Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 126. UAE Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 127. Rest of Middle East Africa Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 128. Rest of Middle East Africa Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 129. Rest of Middle East Africa Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 130. Rest of Middle East Africa Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 131. South & Central America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 132. South & Central America Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 133. South & Central America Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 134. South & Central America Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 135. Brazil Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 136. Brazil Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 137. Brazil Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 138. Brazil Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 139. Argentina Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 140. Argentina Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 141. Argentina Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 142. Argentina Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 143. Rest of South & Central America Lung Cancer Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 144. Rest of South & Central America Lung Cancer Therapy Market, by Minimally Invasive - Revenue and Forecast to 2030 (US$ Million)
Table 145. Rest of South & Central America Lung Cancer Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 146. Rest of South & Central America Lung Cancer Therapy Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 147. Recent Inorganic Growth Strategies in the Lung Cancer Therapy Market
Table 148. Recent Organic Growth Strategies in Lung Cancer Therapy Market
Table 149. Glossary of Terms, Lung Cancer Therapy Market

List Of Figures

Figure 1. Lung Cancer Therapy Market Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. Lung Cancer Therapy Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030
Figure 6. Lung Cancer Therapy Market Revenue, Geography (US$ Mn), 2022 - 2030
Figure 7. Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 8. Non-Invasive Therapy: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Minimally Invasive: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 11. Non-Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 14. Hospitals: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Oncology Clinics: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Research Centers: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America: Lung Cancer Therapy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. North America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 21. US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Europe Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 25. Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Europe Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 27. UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Asia Pacific Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 35. Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Asia Pacific Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 37. China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 45. Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 46. Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 47. Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 49. Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 50. Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 51. Middle East & Africa Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 52. Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. Middle East & Africa Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 54. Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 56. UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 57. Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 58. South & Central America Lung Cancer Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 59. South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 60. South & Central America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 61. Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 62. Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 63. Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 64. Growth Strategies in Lung Cancer Therapy Market

Product Code: TIPRE00030093

The lung cancer therapy market is expected to grow from US$ 31.018 billion in 2022 to US$ 80.493 billion by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030.

Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. In May 2021, the US Food and Drug Administration approved Lumakras (sotorasib), the first treatment for adult non-small cell lung cancer patients. This therapy is given to patients who have KRAS G12C mutation and have received at least one prior systemic therapy. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.

Government Initiatives for Screening and Treatment of Lung Cancer drives the growth the Lung Cancer Therapy Market

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer.

As per United States Preventive Services Task Force (USPSTF), people from the age range of 50-80 with a smoking history of 20 packs per year, either presently smoking or having quit within the last 15 years, are more susceptible to developing lung cancer in the US. Hence, the United States Preventive Services Task Force (USPSTF) recommends these people undergo low-dose computed tomography (LDCT) screening for lung cancer every year to ensure the early detection of lung cancer. In addition, in July 2022, the Biden Administration in the US introduced a new model that aims to improve cancer care and lower the treatment cost for patients who are covered under Medicare services.

In July 2021, Cancer Australia partnered with the Department of Health and Aged Care to evaluate the feasibility of a lung cancer screening program in Australia. After obtaining positive results of the feasibility assessment, in May 2023, the Department of Health and Aged Care, the Government of Australia, declared an investment of US$ 263.8 million for 2023-2024 for the implementation of the National Lung Cancer Screening Program across the country. Through this program, the Department of Health and Aged Care focuses on the prevention and early detection of lung cancer. Further, the Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients.

Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the lung cancer therapy market.

The lung cancer therapy market is divided on the basis of therapy type, indication, end user, and geography. The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. The market, by end user, is segmented into hospitals, oncology clinics, research centers, and others.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the lung cancer therapy market. North America accounts for a significant market share owing to the growing incidences of lung cancer cases due to increase in smoking, consumption of tobacco, and increase in air pollution due to industrialization. The growth of the lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.

Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.

As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through "Rural Appalachian Lung Cancer Screening Initiative." The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the lung cancer therapy market in the US.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and United States Preventive Services Task Force (USPSTF) are a few key primary and secondary sources referred to while preparing the report on the lung cancer therapy market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the lung cancer therapy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the lung cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the lung cancer therapy market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Lung Cancer Therapy Market, by Geography

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Lung Cancer Therapy Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. Lung Cancer Therapy Market - Key Industry Dynamics

5.1 Market Drivers:
- 5.1.1 Increase in Cases of Lung Cancer
- 5.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
5.2 Market Restraints
- 5.2.1 High Cost of Lung Cancer Therapy
5.3 Market Opportunities
- 5.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
5.4 Future Trends
- 5.4.1 Growing Demand for Targeted Therapy
5.5 Impact Analysis:

6. Lung Cancer Therapy Market - Global Market Analysis

6.1 Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

7. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
7.3 Non-Invasive Therapy
- 7.3.1 Overview
- 7.3.2 Non-Invasive Therapy: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Minimally Invasive
- 7.4.1 Overview
- 7.4.2 Minimally Invasive: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.1 Global: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

8. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

8.1 Overview
8.2 Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Non-Small Cell Lung Cancer
- 8.3.1 Overview
- 8.3.2 Non-Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Small Cell Lung Cancer
- 8.4.1 Overview
- 8.4.2 Small Cell Lung Cancer: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Oncology Clinics
- 9.4.1 Overview
- 9.4.2 Oncology Clinics: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Research Centers
- 9.5.1 Overview
- 9.5.2 Research Centers: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. Lung Cancer Therapy Market - Geographical Analysis

10.1 North America Lung Cancer Therapy Market, Revenue and Forecast To 2030
- 10.1.1 Overview
- 10.1.2 North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.3 North America: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 10.1.3.1 North America: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
- 10.1.4 North America: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.1.5 North America: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 10.1.6 North America Lung Cancer Therapy Market, by Country
  - 10.1.6.1 US
    - 10.1.6.1.1 Overview
    - 10.1.6.1.2 US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.1.3 US: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.6.1.3.1 US: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.1.6.1.4 US: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.6.1.5 US: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.1.6.2 Canada
    - 10.1.6.2.1 Overview
    - 10.1.6.2.2 Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.2.3 Canada: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.6.2.3.1 Canada: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.1.6.2.4 Canada: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.6.2.5 Canada: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.1.6.3 Mexico
    - 10.1.6.3.1 Overview
    - 10.1.6.3.2 Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.3.3 Mexico: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.1.6.3.3.1 Mexico: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.1.6.3.4 Mexico: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.1.6.3.5 Mexico: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
10.2 Europe Lung Cancer Therapy Market, Revenue and Forecast to 2030
- 10.2.1 Overview
- 10.2.2 Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.2.3 Europe: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 10.2.3.1 Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
- 10.2.4 Europe: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.2.5 Europe: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 10.2.6 Europe Lung Cancer Therapy Market, by Country
  - 10.2.6.1 UK
    - 10.2.6.1.1 Overview
    - 10.2.6.1.2 UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.1.3 UK: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.6.1.3.1 UK: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.2.6.1.4 UK: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.6.1.5 UK: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.2 Germany
    - 10.2.6.2.1 Overview
    - 10.2.6.2.2 Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.2.3 Germany: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.6.2.3.1 Germany: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.2.6.2.4 Germany: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.6.2.5 Germany: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.3 France
    - 10.2.6.3.1 Overview
    - 10.2.6.3.2 France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.3.3 France: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.6.3.3.1 France: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.2.6.3.4 France: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.6.3.5 France: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.4 Italy
    - 10.2.6.4.1 Overview
    - 10.2.6.4.2 Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.4.3 Italy: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.6.4.3.1 Italy: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.2.6.4.4 Italy: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.6.4.5 Italy: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.5 Spain
    - 10.2.6.5.1 Overview
    - 10.2.6.5.2 Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.5.3 Spain: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.6.5.3.1 Spain: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.2.6.5.4 Spain: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.6.5.5 Spain: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.6 Russia
    - 10.2.6.6.1 Overview
    - 10.2.6.6.2 Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.6.3 Russia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.6.6.3.1 Russia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.2.6.6.4 Russia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.6.6.5 Russia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.2.6.7 Rest of Europe
    - 10.2.6.7.1 Overview
    - 10.2.6.7.2 Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.7.3 Rest of Europe: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.2.6.7.3.1 Rest of Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.2.6.7.4 Rest of Europe: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.2.6.7.5 Rest of Europe: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
10.3 Asia Pacific Lung Cancer Therapy Market, Revenue and Forecast to 2030
- 10.3.1 Overview
- 10.3.2 Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.3.3 Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 10.3.3.1 Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
- 10.3.4 Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.3.5 Asia Pacific: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 10.3.6 Asia Pacific Lung Cancer Therapy Market, by Country
  - 10.3.6.1 China
    - 10.3.6.1.1 Overview
    - 10.3.6.1.2 China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.1.3 China: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.1.3.1 China: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.1.4 China: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.1.5 China: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.2 Japan
    - 10.3.6.2.1 Overview
    - 10.3.6.2.2 Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.2.3 Japan: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.2.3.1 Japan: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.2.4 Japan: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.2.5 Japan: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.3 India
    - 10.3.6.3.1 Overview
    - 10.3.6.3.2 India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.3.3 India: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.3.3.1 India: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.3.4 India: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.3.5 India: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.4 Australia
    - 10.3.6.4.1 Overview
    - 10.3.6.4.2 Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.4.3 Australia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.4.3.1 Australia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.4.4 Australia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.4.5 Australia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.5 South Korea
    - 10.3.6.5.1 Overview
    - 10.3.6.5.2 South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.5.3 South Korea: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.5.3.1 South Korea: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.5.4 South Korea: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.5.5 South Korea: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.6 Southeast Asia
    - 10.3.6.6.1 Overview
    - 10.3.6.6.2 Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.3 Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.3.1 Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.4 Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.5 Southeast Asia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    - 10.3.6.6.6 Singapore
    - 10.3.6.6.6.1 Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.6.2 Singapore: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.6.2.1 Singapore: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.6.3 Singapore: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.6.4 Singapore: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    - 10.3.6.6.7 Malaysia
    - 10.3.6.6.7.1 Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.7.2 Malaysia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.7.2.1 Malaysia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.7.3 Malaysia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.7.4 Malaysia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    - 10.3.6.6.8 Indonesia
    - 10.3.6.6.8.1 Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.8.2 Indonesia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.8.2.1 Indonesia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.8.3 Indonesia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.8.4 Indonesia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    - 10.3.6.6.9 Vietnam
    - 10.3.6.6.9.1 Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.9.2 Vietnam: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.9.2.1 Vietnam: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.9.3 Vietnam: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.9.4 Vietnam: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    - 10.3.6.6.10 Cambodia
    - 10.3.6.6.10.1 Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.10.2 Cambodia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.10.2.1 Cambodia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.10.3 Cambodia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.10.4 Cambodia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    - 10.3.6.6.11 Philippines
    - 10.3.6.6.11.1 Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.11.2 Philippines: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.11.2.1 Philippines: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.11.3 Philippines: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.11.4 Philippines: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
    - 10.3.6.6.12 Rest of Southeast Asia
    - 10.3.6.6.12.1 Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.12.2 Rest of Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.6.12.2.1 Rest of Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.6.12.3 Rest of Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.6.12.4 Rest of Southeast Asia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.3.6.7 Rest of Asia Pacific
    - 10.3.6.7.1 Overview
    - 10.3.6.7.2 Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.7.3 Rest of Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.3.6.7.3.1 Rest of Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.3.6.7.4 Rest of Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.3.6.7.5 Rest of Asia Pacific: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
10.4 Middle East & Africa Lung Cancer Therapy Market, Revenue and Forecast to 2030
- 10.4.1 Overview
- 10.4.2 Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.4.3 Middle East & Africa: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 10.4.3.1 Middle East & Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
- 10.4.4 Middle East & Africa: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.4.5 Middle East & Africa: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.1 Middle East & Africa Lung Cancer Therapy Market, by Country
  - 10.4.5.2 Saudi Arabia
    - 10.4.5.2.1 Overview
    - 10.4.5.2.2 Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.2.3 Saudi Arabia: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.2.3.1 Saudi Arabia: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.4.5.2.4 Saudi Arabia: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.2.5 Saudi Arabia: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.3 South Africa
    - 10.4.5.3.1 Overview
    - 10.4.5.3.2 South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.3.3 South Africa: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.3.3.1 South Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.4.5.3.4 South Africa: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.3.5 South Africa: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.4 UAE
    - 10.4.5.4.1 Overview
    - 10.4.5.4.2 UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.4.3 UAE: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.4.3.1 UAE: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.4.5.4.4 UAE: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.4.5 UAE: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.4.5.5 Rest of Middle East Africa
    - 10.4.5.5.1 Overview
    - 10.4.5.5.2 Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.5.5.3 Rest of Middle East Africa: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.4.5.5.3.1 Rest of Middle East Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.4.5.5.4 Rest of Middle East Africa: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.4.5.5.5 Rest of Middle East Africa: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
10.5 South & Central America Lung Cancer Therapy Market, Revenue and Forecast to 2030
- 10.5.1 Overview
- 10.5.2 South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
- 10.5.3 South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
  - 10.5.3.1 South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
- 10.5.4 South & Central America: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
- 10.5.5 South & Central America: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
- 10.5.6 South & Central America Lung Cancer Therapy Market, by Country
  - 10.5.6.1 Brazil
    - 10.5.6.1.1 Overview
    - 10.5.6.1.2 Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.1.3 Brazil: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.5.6.1.3.1 Brazil: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.5.6.1.4 Brazil: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.5.6.1.5 Brazil: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.5.6.2 Argentina
    - 10.5.6.2.1 Overview
    - 10.5.6.2.2 Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.2.3 Argentina: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.5.6.2.3.1 Argentina: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.5.6.2.4 Argentina: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.5.6.2.5 Argentina: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
  - 10.5.6.3 Rest of South & Central America
    - 10.5.6.3.1 Overview
    - 10.5.6.3.2 Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.3.3 Rest of South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
    - 10.5.6.3.3.1 Rest of South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
    - 10.5.6.3.4 Rest of South & Central America: Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
    - 10.5.6.3.5 Rest of South & Central America: Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)

11. Lung Cancer Therapy Market - Industry Landscape

11.1 Overview
11.2 Growth Strategies in Lung Cancer Therapy Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Medtronic Plc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 RF Medical Co Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Johnson & Johnson
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Merck KGaA
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Sun Pharmaceutical Industries Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Bioventus Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Olympus Corp
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Meiji Seika Pharma Co Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Advanz Pharma Corp
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

肺がん治療の世界市場：市場規模・予測、世界・地域別シェア、動向、成長機会、分析範囲：治療の種類別・適応症別・エンドユーザー別・地域別

Lung Cancer Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, Indication, End User, and Geography

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章肺がん治療の市場情勢

第5章肺がん治療市場：主な産業力学

第6章肺がん治療市場：世界市場の分析

第7章世界の肺がん治療市場の収益と予測：治療の種類別 (2030年まで)

第8章世界の肺がん治療市場の収益と予測：適応症別 (2030年まで)

第9章世界の肺がん治療市場の収益と予測：エンドユーザー別 (2030年まで)

第10章肺がん治療市場：地域別分析

第11章肺がん治療市場：業界情勢

第12章企業プロファイル

第13章付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Lung Cancer Therapy Market Landscape

5. Lung Cancer Therapy Market - Key Industry Dynamics

6. Lung Cancer Therapy Market - Global Market Analysis

7. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

8. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

9. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

10. Lung Cancer Therapy Market - Geographical Analysis

11. Lung Cancer Therapy Market - Industry Landscape

12. Company Profiles

13. Appendix

肺がん治療の世界市場：市場規模・予測、世界・地域別シェア、動向、成長機会、分析範囲：治療の種類別・適応症別・エンドユーザー別・地域別

Lung Cancer Therapy Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type, Indication, End User, and Geography

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 肺がん治療の市場情勢

第5章 肺がん治療市場：主な産業力学

第6章 肺がん治療市場：世界市場の分析

第7章 世界の肺がん治療市場の収益と予測：治療の種類別 (2030年まで)

第8章 世界の肺がん治療市場の収益と予測：適応症別 (2030年まで)

第9章 世界の肺がん治療市場の収益と予測：エンドユーザー別 (2030年まで)

第10章 肺がん治療市場：地域別分析

第11章 肺がん治療市場：業界情勢

第12章 企業プロファイル

第13章 付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Lung Cancer Therapy Market Landscape

5. Lung Cancer Therapy Market - Key Industry Dynamics

6. Lung Cancer Therapy Market - Global Market Analysis

7. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

8. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

9. Global Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

10. Lung Cancer Therapy Market - Geographical Analysis

11. Lung Cancer Therapy Market - Industry Landscape

12. Company Profiles

13. Appendix

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章肺がん治療の市場情勢

第5章肺がん治療市場：主な産業力学

第6章肺がん治療市場：世界市場の分析

第7章世界の肺がん治療市場の収益と予測：治療の種類別 (2030年まで)

第8章世界の肺がん治療市場の収益と予測：適応症別 (2030年まで)

第9章世界の肺がん治療市場の収益と予測：エンドユーザー別 (2030年まで)

第10章肺がん治療市場：地域別分析

第11章肺がん治療市場：業界情勢

第12章企業プロファイル

第13章付録